London, 29 May 2015: Technavio, the independent tech-focused global research firm, has published a report on the IVD market in the US 2015-2019, which is expected to grow at a CAGR of 5.45% during the forecast period of 2014-2019.
Rapid growth of this market can be attributed to the increase in molecular testing, particularly in the diabetes, oncology, and the infectious disease segment. Increase in geriatric population in the US region is also a major factor that helps to enhance growth of this market. The elderly are susceptible to a multitude of age-related issues, thus, routine screening tests help in identifying these issues in their early stages. This increase in demand is expected to boost market growth.
“A rise in the focus on infection prevention and obtaining accurate results in the healthcare industry will boost the consumption of ready-to-use reagents during the forecast period,” says Faisal Ghaus, Vice President of Technavio.
“Ready-to-use reagents offer advantages such as avoiding calculation, dilution, and pipetting errors and save time. They also help prevent contamination.”
Key Market Drivers:
- Changes in Healthcare System.
- Rise in Geriatric Population.
- Increase in Molecular Testing.
- Increase in Demand for POC Diagnostics.
Key Market Trends:
- Move toward Real-time Personalized Treatment.
- Increase in M&A.
- Ready-to-use Reagents.
Key Market Vendors:
- Abbott Laboratories
- bioMérieux SA
- Danaher Corp.
- Roche Diagnostics
- Siemens Healthcare AG
To define the market circumstances in the next 3-4 years, Technavio analysts have conducted in-depth analysis of the impact of market drivers, challenges and trends featuring data on product segmentations, vendor shares, growth rate by revenue and an evaluation of the different buying criteria in the order of importance.
https://www.technavio.com/%3Cp%3EIf%20you%20are%20interested%20in%20more%…
